Industry Consortium Developing Best Practices For Meeting Proposed EU GMP PUPSIT Requirement
Executive Summary
The pharmaceutical industry is grappling with the fact that, despite their concerns of additional risk, pre-use, post-sterilization integrity testing (PUPSIT) may remain an expectation in the EU's Annex 1. A consortium has been established to help companies address filtration related risks that PUPSIT is designed to mitigate and to develop a best practice guide on PUPSIT to help manufacturers comply with the EU's Annex 1.
You may also be interested in...
Industry Groups Raise Concerns About Proposed EU GMP Annex 1 Revisions
Industry groups have raised some concerns regarding the European Commission's proposed revisions to the EU’s good manufacturing practice guidelines. They want Annex 1 better aligned with other regulatory and compendial standards for cleanroom designations and water for injection. They also want the European Commission to eliminate certain filter testing requirements as well as limits for large particles in cleanrooms. Groups are also concerned about the costs of implementing certain proposed contamination controls.
EU Issues Plans For Significant Changes To Manufacturing Standards For Sterile Medicines
Long-awaited plans to change the EU guideline on manufacturing standards for sterile medicinal products are out for consultation. The proposals were drafted in cooperation with the World Health Organization and the international pharmaceutical inspectorate group, PIC/S, to ensure global alignment of standards.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”